Fig. S3

her1 expression is normal in embryos injected with a control MO, either alone or in combination with a sub-optimal dose of pnrc2 sbMO. Injection of a sub-optimal dose of pnrc2 sbMO (2 ng) has little to no effect on her1 expression (A, C), contrasting with the expected her1 misexpression observed after injection of a moderate dose of pnrc2 sbMO (6 ng) (B). Injection of a moderate dose of an unrelated sbMO targeting rbfox1l (6 ng) either alone (D) or combined with a sub-optimal dose of pnrc2 sbMO (2 ng) has no effect on her1 expression (E). The proportion affected in each condition is plotted on a bar graph that indicates significant differences between single morphants, double morphants, and controls (F). To confirm effective rbfox1l knockdown, we co-injected rbfox1l and rbfox2 sbMOs (6 ng each) in parallel experiments (neither sbMO produces an overt morphological phenotype when injected alone) and observed the expected paralysis phenotype in all double-injected embryos (n=27/27 paralyzed embryos at 24 hpf) (Gallagher et al, 2011; Berberoglu et al, 2017), confirming that we were using an effective rbfoxl1 sbMO dose in our experiments. sbMO = splice-blocking MO; **** = p<0.0001.